Emma Rachelle Surber - Comment
Posted : 11/22/2011     ID ：FDA-2011-N-0583-0002     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Depomed, Inc. - Comment
Posted : 02/06/2012     ID ：FDA-2011-N-0583-0003     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Shire Human Genetic Therapies - Comment
Posted : 02/06/2012     ID ：FDA-2011-N-0583-0004     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Catholic Health Initiatives - Comment
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0005     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

GlaxoSmithKline GSK - Comment
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0006     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Pharmaceutical Research and Manufacturers of America (PhRMA) - Comment
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0007     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Plasma Protein Therapeutics Association (PPTA) - Comment
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0008     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Pfizer Inc - Comment
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0009     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Novartis - Comment
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0010     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Biotechnology Industry Organization (BIO) - Comment
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0011     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Shire HGT - Comment re FDA-2011-N-0583-0004
Posted : 02/15/2012     ID ：FDA-2011-N-0583-0012     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET

Buchanan Ingersoll & Rooney PC - Comment
Posted : 04/23/2012     ID ：FDA-2011-N-0583-0013     Agency : FDA

Comment Period Closed
Jan 17,2012 11:59 PM ET